Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Protoxin-I (ProTx-I) is a 35-amino acid peptide toxin originally isolated from the venom of the Peruvian green velvet tarantula (*Thrixopelma pruriens*). It belongs to the inhibitory cystine knot (ICK) family of peptides. ProTx-I acts as a potent, non-selective inhibitor of various voltage-gated sodium (Nav) channels, including Nav1.1, Nav1.2, Nav1.5, Nav1.7, and Nav1.8. It functions as a gating modifier by binding to the voltage-sensor domains (VSDs) of these channels, specifically shifting the voltage dependence of activation toward more depolarized potentials. In addition to sodium channels, ProTx-I has been shown to inhibit T-type voltage-gated calcium channels (Cav3.1). Although primarily used as a high-affinity pharmacological tool in research, it is studied for its potential to inhibit metastasis in sodium-regulated cancers and its role in modulating nociceptive signaling for pain management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on protoxin-I.